Biocryst Pharmaceuticals Inc
BCRX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000882796
No open-market purchases or sales by Biocryst Pharmaceuticals Inc insiders were filed in the last 90 days; 319 institutions reported holding it in 13F filings for Q2 2026, worth $2.61B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Biocryst Pharmaceuticals Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Biocryst Pharmaceuticals Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Stonehouse Jon P | Director | 1,340,419 | Sep 2, 2026 | 7 |
| Milne Jill C. | Director | 33,226 | Sep 2, 2026 | 5 |
| Milano Vincent | Director | 109,642 | Sep 2, 2026 | 5 |
| McKee Amy E | Director | 47,821 | Sep 2, 2026 | 6 |
| Frank Steven | Director | 36,747 | Sep 2, 2026 | 5 |
| Levin Alan G | Director | 79,565 | Jun 15, 2026 | 1 |
| Galson Steven K | Director | 27,794 | Jun 15, 2026 | 1 |
| Sanders Machelle | Director | 45,936 | Jun 15, 2026 | 2 |
| Heggie Theresa | Director | 80,646 | Jun 15, 2026 | 2 |
| Barnes Alane P | Chief Legal Officer | 400,703 | May 15, 2026 | 6 |
| Menon Sandeep | Chief R&D Officer | 205,150 | Apr 7, 2026 | 1 |
| Gayer Charles K | President and CCO | 952,583 | Dec 23, 2025 | 3 |
| Ghias Babar | Chief Financial Officer | 268,700 | Dec 19, 2025 | 1 |
| Hutson Nancy J | Director | 99,138 | Jun 16, 2025 | 0 |
| Thackray Helen M. | Chief R&D Officer | 377,318 | Apr 2, 2025 | 0 |
| Doyle Anthony | Chief Financial Officer | 377,867 | Dec 23, 2024 | 0 |
| Aselage Steve | Director | 70,159 | Jun 14, 2024 | 0 |
| Abercrombie George B | Director | 36,431 | Jun 14, 2024 | 0 |
| Lee Kenneth B Jr | Director | 68,863 | Jun 15, 2023 | 0 |
| Ingram Robert Alexander | Director | 100,198 | Mar 2, 2023 | 0 |
| Jones Michael L | Exec. Director, Finance - PAO | 16,653 | Dec 21, 2022 | 0 |
| Babu Yarlagadda S | Chief Discovery Officer | 298,541 | Nov 16, 2022 | 0 |
| Sheridan William P | Chief Medical Officer | 37,954 | Mar 14, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 15, 2026 (view filing) | May 13 | 2 days | Barnes Alane PChief Legal Officer | SSale | −62.5K | $9.54 | −$596.3K | −13.5%400.7K after | 10b5-1 |
| May 19, 2026 (view filing) | May 18 | 1 day | McKee Amy EDirector | SSale | −11.2K | $8.97 | −$100.3K | −26.3%31.3K after |